DURHAM, N.C. & LIEGE, Belgium--(BUSINESS WIRE)--MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDx™ for Brain) was shown to be the only prognostic factor for overall survival (OS) in newly diagnosed glioblastoma multiforme (GBM) patients over the age of 70 in a study published in the Journal of Clinical Oncology (JCO)*, one of the leading cancer journals. Prognostic factors are biological markers that help determine the course and outcome of disease. The study was conducted by eight of the foremost French academic institutions to evaluate the efficacy and safety of temozolomide alone in what is considered a fragile patient population, suffering from this devastating type of brain cancer.
